Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the bioavailability of Azacitidine for Injection
relative to Vidaza® in MDS patients under fasting conditions. The data will be evaluated
statistically to determine if the products meet bioequivalence criteria.